Tag
A comprehensive review of the ACHIEVE-4 trial confirms orforglipron’s cardiovascular safety non-inferior to insulin glargine in type 2 diabetes patients at elevated cardiovascular risk, highlighting its oral administration and safety
This Phase II trial demonstrates that HRS-7535, an oral small-molecule GLP-1 receptor agonist, significantly improves glycaemic control and is well-tolerated in type 2 diabetes patients inadequately controlled with metformin and SGLT2 inhib
Survodutide, a dual glucagon and GLP-1 receptor agonist, demonstrates significant weight loss and glycemic improvements in adults with obesity and type 2 diabetes, offering promise as a novel therapeutic agent with favorable efficacy and sa
Postbariatric hypoglycemia (PBH) is linked to rapid gastric emptying after Roux-en-Y gastric bypass. GLP-1 receptor agonists slow gastric emptying but do not prevent hypoglycemia, highlighting complex metabolic mechanisms in PBH management.
This phase 2b trial evaluates bofanglutide’s efficacy and safety compared to semaglutide in Chinese patients with type 2 diabetes, showing notable HbA1c reductions and manageable gastrointestinal side effects.
This phase 3 trial evaluates the 52-week safety of oral orforglipron in Japanese adults with type 2 diabetes, showing an acceptable safety profile when used alongside diet, exercise, and oral antihyperglycemic drugs.
This study evaluates the clinical benefits of semaglutide, a GLP-1 receptor agonist, as an add-on therapy to insulin in patients with LADA, demonstrating improved glycemic control, BMI reduction, and insulin dose sparing, especially in thos
In a large OHDSI network study of adults with type 2 diabetes, semaglutide was not associated with a higher or lower risk of neovascular age-related macular degeneration.
A large real-world study found GLP-1 receptor agonist use was linked to a lower risk of intracranial aneurysm rupture and milder bleeding severity if rupture occurred.
In a 16-week randomized trial, adjunctive oral semaglutide improved effort-based decision-making in adults with major depressive disorder and overweight or obesity, suggesting a potential role for GLP-1 receptor agonism in reward-related dy
A study reveals that combining GLP-1 receptor agonists with SGLT-2 inhibitors significantly lowers the risk of major adverse liver and cardiovascular outcomes in patients with MASLD and type 2 diabetes compared to monotherapy.
In ATTAIN‑2, oral orforglipron produced dose‑dependent, statistically superior weight loss and improved HbA1c versus placebo over 72 weeks in adults with overweight/obesity and type 2 diabetes, with an adverse‑event profile dominated by gas
In a large retrospective cohort, women who discontinued GLP‑1 receptor agonists shortly before or during early pregnancy had greater gestational weight gain and higher risks of preterm birth, gestational diabetes, and hypertensive disorders
Maternally inherited diabetes and deafness (MIDD) is driven by m.3243A>G mitochondrial mutation with mixed β‑cell failure and insulin resistance. GLP‑1 receptor agonists and SGLT2 inhibitors have biologic plausibility and cardiorenal ben
The phase 3 SURPASS-PEDS trial demonstrates that tirzepatide significantly improves glycaemic control and reduces BMI in children and adolescents with type 2 diabetes, with a safety profile consistent with adult studies.
Orforglipron, a novel oral GLP-1 receptor agonist, demonstrated significant and sustained weight reduction in obese adults without diabetes in a 72-week phase 3 trial, with a tolerable safety profile consistent with existing GLP-1 therapies
Orforglipron demonstrates significant glycemic control and weight reduction benefits in early type 2 diabetes and obesity, with favorable safety and oral administration convenience.
Ecnoglutide, a novel cAMP-biased GLP-1 receptor agonist, demonstrated non-inferior glycemic control and comparable safety to dulaglutide at 52 weeks in type 2 diabetes patients on metformin, offering a promising new treatment option.
Amycretin, a novel dual GLP-1 and amylin receptor agonist, demonstrated safety, tolerability, and dose-proportional pharmacokinetics in adults with overweight or obesity, supporting further trials on its weight loss efficacy.
Maridebart cafraglutide, a novel once-monthly peptide-antibody conjugate, significantly reduces body weight in individuals with obesity, with and without type 2 diabetes, offering a new therapeutic option based on phase 2 trial results.
